Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Fernanda Costa Svedman

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

F. Costa Svedman1, I. Das2, R. Tuominen2, E.D. Ramqvist3, J. Hansson1, V. Höiom2, S. Egyhazi Brage2

Author affiliations

  • 1 Tema Cancer, Karolinska University Hospital-Solna, 171 76 - Solna/SE
  • 2 Depratment Of Oncology And Pathology, Karolinska Institute, 17177 - Stockholm/SE
  • 3 Pathology, Karolinska University Hospital-Solna, 171 76 - Solna/SE
More

Resources

Abstract 3252

Background

Immune checkpoint inhibitors (ICI) have improved clinical outcome for many patients with advanced cutaneous malignant melanoma (CMM) during the last decade. The magnitude and duration of response vary considerably between patients. Predictive biomarkers to identify patients that will benefit from treatment can increase efficacy, diminish side effects and costs. Our aim is to identify predictive biomarkers in tumors samples from patients with advanced CMM receiving ICI.

Methods

Patients with advanced CMM at Karolinska University Hospital, Stockholm, starting therapy with ICI were invited to participate in our study. After signing informed consent a pre-treatment fine needle or core biopsy was taken from an accessible metastasis. RNA was extracted to perform targeted RNA sequencing using the Ion AmpliSeq Transcriptome Human Gene Expression Kit for RefSeq genes. Partek Genomics Suite® software was applied to find differentially expressed genes and correlate the data with therapy response and progression free survival (PFS).

Results

Nineteen patients were included between September2013 and August2017, 8 female and 11 male. The median age was 70 years old (range 49 – 84). All patients had metastatic disease (13 M1c, 4 M1b, 2 M1a). ICI was first-line treatment for 16 patients. Nivolumab or pembrolizumab was given to 17 patients and two received ipilimumab. Five patients had partial response, 3 stable disease and 7 complete response whereas 4 had progressive diasease. Median PFS was 10 months (range 1,2 – 62 months, 6 patients still responding). High expression of a subset of genes playing a role for DNA replication, genes involved in chromatin remodeling and cell cycle were significantly associated with shorter PFS. The correlation between low expression of interferon gamma signature genes and poorer treatment outcome was confirmed in our study.

Conclusions

Our findings suggest that genes involved in the regulation of DNA replication, chromatin remodeling and cell cycle may influence the long-term response to ICI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Karolinska University Hospital and Karolinska Institute.

Funding

The Swedish Cancer Society, the Cancer Research Funds of Radiumhemmet and Knut and Alice Wallenberg foundation. We aknowledge support of the Science for Life Laboratory, National Genomics Infrastructure (NGI)/Uppsala, Genome Center and UPPMAX for providing assistance in massive parallel sequencing and computational infrastructure (work funded by RFI/VR and Scilife, Sweden).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings